{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:13:30Z","timestamp":1792293210679,"version":"4.4.0"},"reference-count":85,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Russian Science Foundation","award":["22-25-00516"],"award-info":[{"award-number":["22-25-00516"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>(1) Background: We aimed to estimate the pooled effectiveness and safety of vaccination in follicular lymphoma (FL) and discuss implications for immunotherapy development. (2) Methods: We included randomized trials (RCTs) of therapeutic vaccines in patients with FL. Progression-free survival (PFS) was the primary outcome. We searched databases (PubMed, Embase, Scopus, Web of Science Core, medRxiv) and registries (PROSPERO, CENTRAL, ClinicalTrials.gov, EuCTR, WHO ICTRP) and conducted online, citation, and manual searches. We assessed risks of bias across outcomes using RoB 2.0 and across studies using ROB-ME and a contour-enhanced funnel plot. (3) Results: Three RCTs were included (813 patients, both previously treated and untreated). Patients with a complete or partial response after chemotherapy were randomized to either a patient-specific recombinant idiotype keyhole limpet hemocyanin (Id-KLH) vaccine plus granulocyte\u2013macrophage colony-stimulating factor (GM-CSF) or placebo immunotherapy (KLH + GM-CSF). Meta-analyses showed that PFS was worse with the vaccine, but not significantly: hazard ratio, 1.09 (95% CI 0.91\u20131.30). The GRADE certainty of evidence was moderate. Adverse event data were mixed. (4) Conclusions: We are moderately certain that Id-KLH results in little to no difference in PFS in FL. (5) Funding: Russian Science Foundation grant #22-25-00516. (6) Registration: PROSPERO CRD42023457528.<\/jats:p>","DOI":"10.3390\/ph17030272","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T10:52:00Z","timestamp":1708512720000},"page":"272","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Vaccines for Follicular Lymphoma: A Systematic Review"],"prefix":"10.3390","volume":"17","author":[{"given":"Andrei","family":"Suponin","sequence":"first","affiliation":[{"name":"RM Gorbacheva Research Institute, Pavlov University, L\u2019va Tolstogo 6-8, 197022 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2767-5123","authenticated-orcid":false,"given":"Pavel","family":"Zhelnov","sequence":"additional","affiliation":[{"name":"Independent Researcher, Mexico City 07780, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem","family":"Potanin","sequence":"additional","affiliation":[{"name":"RM Gorbacheva Research Institute, Pavlov University, L\u2019va Tolstogo 6-8, 197022 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Chekalov","sequence":"additional","affiliation":[{"name":"RM Gorbacheva Research Institute, Pavlov University, L\u2019va Tolstogo 6-8, 197022 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Lomazov","sequence":"additional","affiliation":[{"name":"RM Gorbacheva Research Institute, Pavlov University, L\u2019va Tolstogo 6-8, 197022 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kseniia","family":"Vladimirova","sequence":"additional","affiliation":[{"name":"RM Gorbacheva Research Institute, Pavlov University, L\u2019va Tolstogo 6-8, 197022 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Lepik","sequence":"additional","affiliation":[{"name":"RM Gorbacheva Research Institute, Pavlov University, L\u2019va Tolstogo 6-8, 197022 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-2764","authenticated-orcid":false,"given":"Albert","family":"Muslimov","sequence":"additional","affiliation":[{"name":"RM Gorbacheva Research Institute, Pavlov University, L\u2019va Tolstogo 6-8, 197022 St. Petersburg, Russia"},{"name":"Laboratory of Nano- and Microencapsulation of Biologically Active Substances, Peter the Great St. Petersburg Polytechnic University, Polytechnicheskaya 29, 195251 St. Petersburg, Russia"},{"name":"Center for Molecular and Cell Technologies, Saint-Petersburg Chemical-Pharmaceutical University, Professora Popova 14, 197376 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"ref_1","unstructured":"Hoffman, R., Benz, E.J., Silberstein, L.E., Heslop, H.E., Weitz, J.I., Salama, M.E., and Abutalib, S.A. (2023). Hematology: Basic Principles and Practice, Elsevier. [8th ed.]."},{"key":"ref_2","unstructured":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, and Organisation Mondiale de la Sant\u00e9, Centre International de Recherche Sur le Cancer (2008). World Health Organization Classification of Tumours, International Agency for Research on Cancer. [4th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma Incidence Patterns by WHO Subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma Incidence, Survival and Prevalence 2004\u20132014: Sub-Type Analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/leu.2014.251","article-title":"Follicular Lymphoma in Sweden: Nationwide Improved Survival in the Rituximab Era, Particularly in Elderly Women: A Swedish Lymphoma Registry Study","volume":"29","author":"Peterson","year":"2015","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood.2019001362","article-title":"Analysis of 153 115 Patients with Hematological Malignancies Refines the Spectrum of Familial Risk","volume":"134","author":"Sud","year":"2019","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.critrevonc.2008.01.014","article-title":"Follicular Lymphomas","volume":"66","author":"Vitolo","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin Modifying Gene Mutations in Follicular Lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5581\/1516-8484.20120015","article-title":"Follicular Lymphoma: Treatment and Prognostic Factors","volume":"34","author":"Luminari","year":"2011","journal-title":"Rev. Bras. Hematol. E Hemoter."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly Diagnosed and Relapsed Follicular Lymphoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in Low-Tumor-Burden Follicular Lymphomas Between an Initial No-Treatment Policy, Prednimustine, or Interferon Alfa: A Randomized Study from the Groupe d\u2019Etude Des Lymphomes Folliculaires. Groupe d\u2019Etude Des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-Term Effect of a Watch and Wait Policy Versus Immediate Systemic Treatment for Asymptomatic Advanced-Stage Non-Hodgkin Lymphoma: A Randomised Controlled Trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"ref_14","first-page":"CD003805","article-title":"Chemotherapy Plus Rituximab Versus Chemotherapy Alone for B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"2007","author":"Schulz","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab Plus Lenalidomide in Advanced Untreated Follicular Lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and Efficacy of Mosunetuzumab, a Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma: A Single-Arm, Multicentre, Phase 2 Study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100826","DOI":"10.1016\/j.currproblcancer.2021.100826","article-title":"CAR T-Cell Therapy for B-Cell Lymphoma","volume":"46","author":"Denlinger","year":"2022","journal-title":"Curr. Probl. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"204062072211421","DOI":"10.1177\/20406207221142133","article-title":"CAR T-Cell Therapy for Follicular Lymphoma and Mantle Cell Lymphoma","volume":"13","author":"Mohty","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2147\/CMAR.S368588","article-title":"Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes","volume":"15","author":"Mohty","year":"2023","journal-title":"Cancer Manag. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2021014375","article-title":"Comparative Effectiveness of ZUMA-5 (Axi-Cel) Vs SCHOLAR-5 External Control in Relapsed\/Refractory Follicular Lymphoma","volume":"140","author":"Ghione","year":"2022","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer Vaccines as Promising Immuno-Therapeutics: Platforms and Current Progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the Corner on Therapeutic Cancer Vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"Npj Vaccines"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.ctrv.2022.102429","article-title":"Therapeutic Cancer Vaccines: From Biological Mechanisms and Engineering to Ongoing Clinical Trials","volume":"109","author":"Sobhani","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Le, I., Dhandayuthapani, S., Chacon, J., Eiring, A.M., and Gadad, S.S. (2022). Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics. Vaccines, 10.","DOI":"10.3390\/vaccines10050816"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1080\/10428194.2020.1805113","article-title":"Therapeutic Vaccines for Aggressive B-Cell Lymphoma","volume":"61","author":"Young","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients with Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11523-020-00788-w","article-title":"Vaccine Therapies for Cancer: Then and Now","volume":"16","author":"Morse","year":"2021","journal-title":"Target. Oncol."},{"key":"ref_29","unstructured":"Higgins, J., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M., and Welch, V. (2024, February 15). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023). Available online: www.training.cochrane.org\/handbook."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: An Extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e068791","DOI":"10.1136\/bmj-2021-068791","article-title":"Searching Clinical Trials Registers: Guide for Systematic Reviewers","volume":"377","author":"Hunter","year":"2022","journal-title":"BMJ"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2008.19.8903","article-title":"Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients with Follicular Lymphoma","volume":"27","author":"Freedman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","article-title":"Vaccination with Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma","volume":"29","author":"Schuster","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.2012.43.9273","article-title":"Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma","volume":"32","author":"Levy","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_36","first-page":"CD00655","article-title":"Rituximab as Maintenance Therapy for Patients with Follicular Lymphoma","volume":"2009","author":"Vidal","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_37","first-page":"CD008909","article-title":"Anthracycline-Containing Regimens for Treatment of Follicular Lymphoma in Adults","volume":"2013","author":"Itchaki","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_38","first-page":"CD004629","article-title":"Interferon-Alpha for Maintenance of Follicular Lymphoma","volume":"2010","author":"Baldo","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_39","first-page":"CD013377","article-title":"Therapeutic Vaccines for Advanced Non-Small Cell Lung Cancer","volume":"2019","author":"Uranga","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Suponin, A., Zhelnov, P., Potanin, A., Chekalov, A., Lomazov, A., Vladimirova, K., Lepik, K., and Muslimov, A. (2024, February 15). Therapeutic Vaccines for Follicular Lymphoma: A Systematic Review. Available online: https:\/\/osf.io\/kbzfw\/.","DOI":"10.31219\/osf.io\/evj59"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A Web and Mobile App for Systematic Reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jclinepi.2020.01.008","article-title":"A Full Systematic Review Was Completed in 2 Weeks Using Automation Tools: A Case Study","volume":"121","author":"Clark","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2046-4053-4-6","article-title":"Better Duplicate Detection for Systematic Reviewers: Evaluation of Systematic Review Assistant-Deduplication Module","volume":"4","author":"Rathbone","year":"2015","journal-title":"Syst. Rev."},{"key":"ref_44","unstructured":"(2023, October 10). Systematic Review Accelerator: Deduplicator. Available online: https:\/\/sr-accelerator.com\/#\/deduplicator."},{"key":"ref_45","unstructured":"(2023, September 10). Github Taren Sanders\u2019 RobotSearch. Available online: https:\/\/github.com\/tarensanders\/robotsearch."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine Learning for Identifying Randomized Controlled Trials: An Evaluation and Practitioner\u2019s Guide","volume":"9","author":"Marshall","year":"2018","journal-title":"Res. Synth. Methods"},{"key":"ref_47","unstructured":"(2023, May 19). RANDOM.ORG\u2014Integer Set Generator. Available online: https:\/\/www.random.org\/integer-sets\/?mode=advanced."},{"key":"ref_48","unstructured":"Rotondi, M.A. (2023, May 02). kappaSize: Sample Size Estimation Functions for Studies of Interobserver Agreement 2018. Available online: https:\/\/CRAN.R-project.org\/package=kappaSize."},{"key":"ref_49","unstructured":"(2023, May 20). Randolph\u2019s Kappa Calculator. Available online: http:\/\/justus.randolph.name\/kappa."},{"key":"ref_50","unstructured":"(2023, September 25). Github Rayyan_tools. Available online: https:\/\/github.com\/Andreyhok\/rayyan_tools."},{"key":"ref_51","unstructured":"(2023, August 07). DeepL Translate. Available online: https:\/\/www.deepl.com\/translator\/files."},{"key":"ref_52","unstructured":"(2023, October 15). Follicular-Lymphoma-Vaccines Sysrev. Available online: https:\/\/sysrev.com\/u\/11470\/p\/123185."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Masson, D., Malacria, S., Vogel, D., Lank, E., and Casiez, G. ChartDetective: Easy and Accurate Interactive Data Extraction from Complex Vector Charts. Proceedings of the 2023 CHI Conference on Human Factors in Computing Systems, Hamburg, Germany, 23\u201328 April 2023.","DOI":"10.1145\/3544548.3581113"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised Response Criteria for Malignant Lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Robvis: An R Package and Web Application for Visualising Risk-of-Bias Assessments 2019","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"ref_57","unstructured":"Therneau, T. (2024, February 15). A Package for Survival Analysis in R. Available online: https:\/\/CRAN.R-project.org\/package=survival."},{"key":"ref_58","unstructured":"Terry, M.T., and Patricia, M. (2000). Grambsch Modeling Survival Data: Extending the Cox Model, Springer."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to Perform a Meta-Analysis with R: A Practical Tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"key":"ref_60","unstructured":"Kassambara, A., Kosinski, M., Biecek, P., and Fabian, S. (2024, February 15). survminer: Survival Analysis and Visualization, version 0.4.9; 2021. Available online: https:\/\/rpkgs.datanovia.com\/survminer\/index.html."},{"key":"ref_61","unstructured":"Gordon, M., and Lumley, T. (2024, February 15). forestplot: Advanced Forest Plot Using \u2019Grid\u2019 Graphics, Version 3.1.3; 2023. Available online: https:\/\/gforge.se\/packages\/."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e076754","DOI":"10.1136\/bmj-2023-076754","article-title":"ROB-ME: A Tool for Assessing Risk of Bias Due to Missing Evidence in Systematic Reviews with Meta-Analysis","volume":"383","author":"Page","year":"2023","journal-title":"BMJ"},{"key":"ref_63","unstructured":"(2024, February 15). Guideline Development Tool. Available online: https:\/\/gdt.gradepro.org\/."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000063968","article-title":"a) 3.2.2 Psycho-Onkologie b) 3.2.3 Tumorspezifische Immuntherapie","volume":"23","author":"Stein","year":"2000","journal-title":"Oncol. Res. Treat."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF02712691","article-title":"Vacunaci\u00f3n Idiot\u00edpica En Linfomas B de Bajo Grado: Una Nueva Terapia Antitumoral","volume":"3","author":"Cabrera","year":"2001","journal-title":"Rev. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3816\/CLM.2005.n.031","article-title":"Phase III Randomized Trial of Patient-Specific Vaccination for Previously Untreated Patients with Follicular Lymphoma in First Complete Remission: Protocol Summary and Interim Report","volume":"6","author":"Neelapu","year":"2005","journal-title":"Clin. Lymphoma"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/blood.V110.11.4500.4500","article-title":"BiovaxId Vaccine Therapy of Follicular Lymphoma in First Remission: Phase III Blinded Safety Update","volume":"110","author":"Stergiou","year":"2007","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1200\/jco.2009.27.18_suppl.2","article-title":"Idiotype Vaccine Therapy (BiovaxID) in Follicular Lymphoma in First Complete Remission: Phase III Clinical Trial Results","volume":"27","author":"Schuster","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V116.21.429.429","article-title":"Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration in Follicular Lymphoma Patients","volume":"116","author":"Schuster","year":"2010","journal-title":"Blood"},{"key":"ref_70","unstructured":"Biovest International (2024, February 15). Randomized Trial of Patient-Specific Vaccination with Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) with Local GM-CSF in First Complete Remission, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00091676."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/13928","article-title":"Complete Molecular Remissions Induced by Patient-Specific Vaccination Plus Granulocyte-Monocyte Colony-Stimulating Factor Against Lymphoma","volume":"5","author":"Bendandi","year":"1999","journal-title":"Nat. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1182\/blood.V108.11.2756.2756","article-title":"Phase III Trial of Active Immunotherapy (FavId\u00ae, Id\/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (Pts) with Follicular Non-Hodgkin\u2019s Lymphoma (FNHL)","volume":"108","author":"Freedman","year":"2006","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood.V112.11.236.236","article-title":"A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (Id-KLH) and GM-CSF Following Rituximab in Patients with Cd20+ Follicular Lymphoma","volume":"112","author":"Freedman","year":"2008","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1182\/blood.V106.11.2441.2441","article-title":"BiovaxID\u2122 Vaccine Therapy of Follicular Lymphoma in First Remission: Long-Term Follow-Up of a Phase II Trial and Status of a Controlled, Randomized Phase III Trial","volume":"106","author":"Santos","year":"2005","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10428190802563355","article-title":"Tumor-Specific Recombinant Idiotype Immunisation After Chemotherapy as Initial Treatment for Follicular Non-Hodgkin Lymphoma","volume":"50","author":"Timmerman","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V104.11.587.587","article-title":"Id\/KLH Vaccine (FavId\u2122) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRI) and Time-to-Progression (TTP) in Follicular Lymphoma (FL)","volume":"104","author":"Koc","year":"2004","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical Methods for Incorporating Summary Time-to-Event Data into Meta-Analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Guyot, P., Ades, A., Ouwens, M.J., and Welton, N.J. (2012). Enhanced Secondary Analysis of Survival Data: Reconstructing the Data from Published Kaplan-Meier Survival Curves. BMC Med. Res. Methodol., 12.","DOI":"10.1186\/1471-2288-12-9"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Tus\u00e9, D., Ku, N., Bendandi, M., Becerra, C., Collins, R., Langford, N., Sancho, S.I., L\u00f3pez-D\u00edaz De Cerio, A., Pastor, F., and Kandzia, R. (2015). Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma. BioMed Res. Int., 2015.","DOI":"10.1155\/2015\/648143"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1080\/21645515.2017.1285477","article-title":"Phase I Clinical Trial of Idiotypic DNA Vaccine Administered as a Complex with Polyethylenimine to Patients with B-Cell Lymphoma","volume":"13","author":"Meleshko","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Meleshko, A., Piatrouskaya, N., Vashkevich, K., Lutskovich, D., Wang, C., Dormeshkin, D., Savelyeva, N., and Katsin, M. (2022). Safety and Immunogenicity of Combined DNA-Polyethylenimine and Oral Bacterial Idiotypic Vaccine for Patients with B-Cell Non-Hodgkin Lymphoma: A Pilot Study. Cancers, 14.","DOI":"10.3390\/cancers14143298"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1975889","DOI":"10.1080\/2162402X.2021.1975889","article-title":"An Immunogenic First-in-Human Immune Modulatory Vaccine with PD-L1 and PD-L2 Peptides Is Feasible and Shows Early Signs of Efficacy in Follicular Lymphoma","volume":"10","author":"Klausen","year":"2021","journal-title":"OncoImmunology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal Neoantigen Vaccines Induce Persistent Memory T Cell Responses and Epitope Spreading in Patients with Melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.2147\/IJGM.S323576","article-title":"Efficacy and Safety of Actively Personalized Neoantigen Vaccination in the Management of Newly Diagnosed Glioblastoma: A Systematic Review","volume":"14","author":"Khan","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e1230","DOI":"10.1002\/cl2.1230","article-title":"Prisma2020: An R Package and Shiny App for Producing PRISMA 2020-compliant Flow Diagrams, with Interactivity for Optimised Digital Transparency and Open Synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst. Rev."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/3\/272\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:02:31Z","timestamp":1760104951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/3\/272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":85,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ph17030272"],"URL":"https:\/\/doi.org\/10.3390\/ph17030272","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}